

**Preliminary Study of Chronic Myeloid Leukemia
Stem Cells**

Thesis

*Submitted for Partial Fulfillment of the Requirement of M.Sc.
Degree in Internal Medicine.*

Presented by

Hend Nabil Al Lithy
M.B.B.Ch.

Under Supervision of

Professor Dr. Mervat M. Matar
Professor of Internal Medicine and clinical hematology,
Faculty of Medicine,
Cairo University

Professor Dr. Manal M. El Masry
Professor of Clinical Pathology , Faculty of Medicine,
Cairo University

Dr. Mohamed Khalf
Consultant of Clinical Hematology & Head of clinical
Hematology Unit
El Maadi Armed Hospital

Faculty of Medicine
Cairo University
2009

ABSTRACT

Chronic myeloid leukemia (CML) represents an important paradigm for understanding the molecular events leading to malignant transformation of primitive hematopoietic progenitors. LSCs are rare and divide less frequently, and thus, represent a reservoir for relapse and resistance to a molecularly targeted single agent therapy. LSCs are able to evade the majority of current cancer treatments that target rapidly dividing cells. The success of tyrosine kinase inhibitors at controlling the chronic phase disease is tempered somewhat by the persistence of the LSC pool in the majority of the patients. Combined therapies targeting aberrant properties of LSC may obviate therapeutic resistance and relapse in advanced phase and therapeutically recalcitrant CML.

CD7 antigen is expressed on immature myeloid progenitor of chronic phase-chronic myeloid leukaemia patients with inferior survival as a consequence of the more immature CD34⁺CD7⁺ stem cell carrying t(9;22).

Our work is to preliminarily understand the origin of malignant stem cells in CML as well as to study the incidence of very primitive CML stem cells among different CML cases so as to anticipate the ontogeny as well as the prognosis. In addition, this study aims to pave the way for further studies on CML initiating stem cells.

Key words: Chronic Myeloid Leukemia

CD34⁺CD7⁺ stem cells

ACKNOWLEDGMENT

"FIRST OF ALL THANK GOD"

I thank God for all his blessings and givings, particularly the blessing of being surrounded by loving, supportive family and friends who help me a lot.

I would like to express my admiration and deepest gratitude to my dear **professor Dr. Mervat Matar**, Professor of Internal Medicine and clinical hematology-Cairo University, for her guidance, encouragement, kindness and patience, her help can never be forgotten and working under her supervision had been a great honor and indeed a great privilege. Her sincere attitude and gentleness will always be inspiring to me.

I would like to express my sincere gratitude and admiration to **Professor Dr. Manal El Masry**, Professor of Clinical Pathology, Cairo University for her guidance and kindness.

I am grateful for the skill and help of **Dr Mohamed Khalaf**.
Consultant of clinical hematology and Head of clinical Hematology unit,
Maadi Armed Hospital.

I would like also to express my grateful and deep thanks to all the staff of Clinical Hematology Unit-Cairo University especially **Professor Mona El Kassas** and **Professor Hadi Goubbran** for their guidance , gentleness and encouragement during my study in this great unit.

CONTENTS

	Page
INTRODUCTION.....	1
REVIEW OF	
LITERATURE.....	4
<i>Chronic myeloid leukemia</i>	4
Historical Background.....	4
Etiology & Pathogenesis.....	7
Natural History	21
Course of the disease.....	24
Clinical Picture	28
Special Clinical Features.....	31
Laboratory findings.....	34
Diagnosis.....	49
Differential Diagnosis.....	51
Treatment.....	55
<i>Stem cells & CML</i>	81
Hematopoietic stem cells.....	81
Origin of CML Clone.....	83
Progenitor Cell Characteristics.....	87
CML stem cells and TKIs.....	91
Patient and methods.....	92
Results.....	94
Discussion.....	118
Conclusion.....	125
Reference.....	126

List of Tables

	Page
Table 1.1: WHO Criteria for accerelated and blastic phase of CML.....	22
Table 1.2: Sokal index for predicting survival.....	26
Table 1.3: Response to treatment on CML.....	59
Table 2.1: Characteristics of human hematopoietic stem cells.....	81
Table 4.1: Age, sex, residence & duration of the disease and clinical data of CML Patients included in this study.....	94
Table 4.2: Clinical data of CML patients included in this study.....	95
Table 4.3: Complete blood counts and WBCs differential of CML patients in this study	95
Table 4.4: WBCs differential of CML patients in this study.....	96
Table 4.5: Bone marrow Aspirate for CML Patients in this study.....	97
Table 4.6: Differntial counts of bone marrow aspirate of CML Patients in this study.....	97
Table 4.7: BCR-ABL In CML Patients in this study.....	98
Table 4.8: CD34 & CD 7 Expression By stem cells of CML Cases included in this study.....	98
Table 4.9: Sokal prognostic score for CML patients in this study.....	99
Table 4.10: Chemistry of CML patients in this study.....	99

Table 4.11: Other blood chemistry of CML patients in this study.....	100
Table 4.12: Abdominal Ultrasonographic finding in CML Patients in this study.....	101
Table 4.13: Descriptive statistics of complete blood count and WBCs differential data of chronic myeloid leukemia patients included in this study.....	103
Table 4.14: Descriptive statistics of Bone Marrow Examination data of chronic myeloid leukemia patients included in this study.....	103
Table 4.15: Descriptive statistics of LDH, UA &TG of chronic myeloid leukemia patients included in this study.....	104
Table 4.16: Descriptive statistics of CD34 expression and Dual expression of CD34 &CD7 of chronic myeloid leukemia patients included in this study.....	104
Table 4.17: Comparison according to the sex for patients included in the study regarding complete blood count and differential WBCs count.....	107
Table 4.18: Comparison according to the sex for patients included in the study regarding Bone marrow examination.....	107
Table 4.19: Comparison according to the sex for patients included in the study regarding Bone marrow examination.....	108

Table 4.20: Comparison according to the age for patients included in the study regarding Complete blood counts and WBCs differential.....	109
Table 4.21: Comparison according to the age for patients included in the study regarding Bone Marrow Examination.....	109
Table 4.22: Comparison according to the age for patients included in the study regarding other laboratory finding.....	110
Table 4.23: Comparison according to the Duration of diagnosis for patients included in the study regarding Complete blood count and WBCs differential.....	111
Table 4.24: Comparison according to the Duration of diagnosis for patients included in the study regarding Bone Marrow Examination.....	111
Table 4.25: Comparison according to the Duration of diagnosis for patients included in the study regarding other laboratory finding.....	112
Table 4.26: Comparison between intermediate and high risk according to Sokal score for patients included in the study regarding complete blood count and differential WBCs count.....	113
Table 4.27: Comparison between intermediate and high risk according to Sokal score for patients included in the study regarding Bone marrow Examination.....	113
Table 4.28: Comparison between intermediate and high risk according to Sokal score for patients included in the study regarding the other laboratory data.....	114
Table 4.29: Comparison between BCR-ABL for patients included in the study regarding the complete blood count and WBCs differential.....	114

Table 4.30: Comparison between BCR-ABL for patients included in the study regarding Bone marrow examination.....	115
Table 4.31: Comparison between BCR-ABL for patients included in the study regarding other laboratory findings.....	115
Table 4.32: ANOVA Study for Dual expression of CD34 & CD7 with variant parameter for the patients included in this study.....	116
Table 4.34: Correlation analysis between dual CD34&CD7 with different parameter for patients included in this study.....	116
Table 4.32 : Correlation analysis between BCR-ABL and CD34 and Dual CD 34&CD7 for patients included in this study.....	116

List for figures

	Page
Figure 1-1: Philadelphia chromosome.....	10
Figure1-2: Mutation of ABL gene on chromosome 9 and BCR gene on chromosom 22, transcribed RNA and translation of fusion protein	12
Figure 1-3: Normal ABL and BCR genes, the three main breakpoint cluster region on chromosome 22 and of the BCR-ABL fusion transcripts.....	14
Figure 1-4: Signal transduction pathways affected by BCR–ABL.....	17
Figure 1-5: Probability of survival and median survival values for apopulation of CML patients classified into three prognostic categories according to the Euro score.....	26
Figure 1-6: Peripheral blood appearances of a patient with CML at diagnosis.....	35
Figure 1-7: Bone marrow aspirate from a patient with Chronic myeloid leukemia...	40
Figure 1-8: Translocations involved in chronic myelogenous leukemia.....	42
Figure 1-9: Interphase florescence in situ hybridization (FISH) of normal and t(9;22) positive nuclei.....	45
Figure 1-10: Mechanism of action of TKIs	58
Figure1-11: Survival after allogeneic transplantation in chronic myeloid leukemia	74
Figure 2-1: Stem cells properties.....	82

Figure 2-2: Normal hematopoiesis scheme.....	82
Figure 2-3: Stages in hematopoietic cells development.....	82
Figure 4-1: Age distribution among the patients in this study.....	94
Figure 4-2: Sex distribution among patients in this study.....	106
Figure 4-3: Two age group of CML Patient in this study	108
Figure 4-4: Classification of patients included in this study according to duration of diagnosis.....	110
Figure 4-5: Classification of the patients included in this study according to Sokal score.....	112
Figure4-6: Correlation between Dual expression of CD34&CD 7 and Bone marrow myeloblasts for patients in this study.....	117
Figure 4-7: Correlation between Dual expression of CD34&CD7 and Hemoglobin for patients in this study.....	117

LIST OF ABBREVIATIONS

1. **ABL:** Abeslon leukemia virus
2. **ALL:** Acute lymphocytic leukemia
3. **AML:** Acute Myeloid Leukemia
4. **AP:** accelerated phase
5. **BC:** blast crisis
6. **BCR:** breakpoint cluster region
7. **BU/CY:** busulfan and cyclophosphamide
8. **CBL:** casitas B-lineage lymphoma
9. **CEL:** Chronic eosinophilic leukemia
10. **CFU-GMs:** colony forming unit-granulocyte-monocytes
11. **CFUs:** colony forming units
12. **CLL:** chronic lymphocytic leukemia
13. **CML:** Chronic myeloid leukemia
14. **CMML:** Chronic myelomonocytic leukemia
15. **CNL:** Chronic Neutrophilic Leukemia
16. **CRKL:** CRK-like protein
17. **DFS:** Disease-free survival
18. **EGBMT:** The European Group for Blood and Marrow Transplantation
19. **ELA2:** elastase
20. **FTBI-CY:** fractionated total body irradiation and cyclophosphamide
21. **GTP:** guanosine triphosphate
22. **GTPase:** guanosine triphosphatase
23. **GVHD:** graft-versus-host disease
24. **GVL:** graft-versus-leukemia
25. **HCT:** hematopoietic cell transplantation
26. **HCT:** Histocompatible transplantation
27. **HPRT:** hypoxanthine phosphoribosyltransferase

- 28.**IFN- α** : interferone alfa
- 29.**IM**: Imatinib
- 30.**IRIS**: International Randomized study of Interferon and STI571
- 31.**JMML**: Juvenile myelomonocytic leukemia
- 32.**KDa**: kilodaltons
- 33.**LAP**: leukocyte alkaline phosphatase
- 34.**LSCs**: Leukemic stem cells
- 35.**LTC-ICs**: long-term culture-initiating cells
- 36.**MAP**: mitogenactivated protein
- 37.**MCP**: monocyte chemotactic protein
- 38.**MIP**: Macrophage inflammatory protein
- 39.**NK**: Natural Killer cells
- 40.**NF**: Nuclear factor
- 41.**NOD**: nonobese diabetic
- 42.**PDGFR**: platelet derived growth factor receptor
- 43. **Ph chromosome**: Philadelphia chromosome
- 44.**PI3K**: phosphatidylinositol-3'-kinase
- 45.**PR3**: proteinase 3
- 46.**RAS**: Rat Sarcoma
- 47.**RT-PCR**: Real time polymerase chain reaction
- 48.**SCF**: Stem Cell Factor
- 49.**SCID**: severe combined immunodeficiency
- 50.**SIS**: simian sarcoma
- 51.**STAT**: signal transducers and activators of transcription
- 52.**TGF- β** : transforming growth factor beta
- 53.**TKIs**: tyrosine kinase inhibitors
- 54.**TLS**: Tumor lysis syndrome

INTRODUCTION

Chronic myeloid leukemia is a hematopoietic malignancy which is resulted from an acquired genetic change in a haemopoietic stem cell. This altered stem cell proliferates and generates a population of differentiated cells that gradually displaces normal haemopoiesis and leads to a greatly expanded total myeloid mass.

Chronic myelogenous leukemia is classified as one of the myeloproliferative disorders. This group of diseases shares several distinct features:

1. They are clonal disorders of hematopoiesis that arise in a hematopoietic stem or early progenitor cell.
2. They are characterized by the dysregulated production of a particular lineage of mature myeloid cells with fairly normal differentiation.
3. They exhibit a variable tendency to progress to acute leukemia.

[Boham et al., 2002]

The risk of developing CML is slightly increased by exposure to high doses of irradiation, as occurred in survivors of the atomic bombs exploded in Japan in 1945, in patients irradiated for ankylosing spondylitis and women with uterine cervical carcinoma who required radiation therapy but, in general, almost all cases must be regarded as 'sporadic' and no predisposing factors are identifiable. In particular, there is no familial predisposition and no definite association with HLA genotypes has been recognized. No contributory infectious agent has been incriminated *[Verfaillie et al., 1999]*.

Chronic myelogenous leukemia (CML) is associated with the Philadelphia chromosome t(9;22)(q34;q11) Philadelphia chromosome resulted from a translocation between chromosome 9 and 22. The gene involved in this translocation was shown to result from fusion of BCR (breakpoint cluster region) gene on chromosome 22 to the ABL (Abelson leukemia virus) gene on chromosome 9, With formation of the BCR-ABL fusion oncogene.

This oncogene codes for a constitutively active cytoplasmic tyrosine kinase, which now believed to be principle cause of the chronic phase of the CML.

This deregulated tyrosine kinase is implicated in the development of CML and has become a primary target for the treatment of this disorder [*Groffen et al., 1984*].

Twenty to 50 percent of patients are asymptomatic, with the disease first being suspected from routine blood tests. Among symptomatic patients, systemic symptoms (fatigue, malaise, weight loss, excessive sweating), abdominal fullness and discomfort are frequent. Bleeding episodes due to platelet dysfunction are common. Tenderness over the lower sternum is sometimes seen. Acute gouty arthritis may also present at this time. Other frequent findings include splenomegaly and anemia [*Savage et al., 1997*].

The clinical hallmark of CML is the uncontrolled production of granulocytes, predominantly neutrophils, but also eosinophils and basophils. The chronic phase is characterized by a large increase in the pool of committed myeloid progenitors, leading to peripheral blood leukocytosis and often thrombocytosis with a prominent left shift in the differential count and basophilia. White blood cell count is usually above 100,000/ μ L (52 and 72 %), and platelet count above 600,000 to 700,000/ μ L (15 and 34%) [*Spiers et al., 1977*].

The leukocyte alkaline phosphatase (LAP) score is abnormally low. Bone marrow aspiration and biopsy in patients with CML in chronic phase shows granulocytic hyperplasia, a non diagnostic finding. Other non-specific bone marrow findings include an increase in reticulin fibrosis and vascularity [*Lundberg et al., 2000*].

In the past, the diagnosis of CML was based largely upon clinical and laboratory criteria, including the presence of splenomegaly, neutrophilic leukocytosis with circulating immature cells of the granulocyte series, basophilia, and low to absent alkaline phosphatase activity in the circulating neutrophils.

However, current diagnostic criteria require detection of the Ph chromosome or its products, the BCR-ABL fusion mRNA or the Bcr-Abl protein. RT-PCR is a highly sensitive technique that employs specific primers to amplify a DNA fragment from BCR-ABL mRNA transcripts; it is becoming the diagnostic test of choice for Ph-positive leukemia [*Goldman et al., 1999*].

The disease has a triphasic clinical course: a chronic phase, which is present at the time of diagnosis in approximately 85 percent of patients; an accelerated phase, in which neutrophil differentiation becomes progressively impaired and leukocyte counts are more difficult to control with myelosuppressive medications; and blast crisis, a condition resembling acute leukemia in which myeloid or lymphoid blasts fail to differentiate. Without treatment, CML progresses from an initial chronic phase followed by advanced phases of disease (accelerated phase and blast crisis) [*Giles et al., 2004*].

Until the 1980s, CML was generally assumed to be incurable and was treated palliatively in the early days with radiotherapy, and more recently with alkylating agents, notably busulphan and hydroxyurea [*Kennedy, 1992*].

The introduction of imatinib into clinical practice in 1998 was an important therapeutic advance, as with this agent most patients achieve a complete cytogenetic response and may expect prolongation of survival compared with other methods of treatment [*Michael, 2008*].

Treatment options for patients with CML are varied and include: potential cure with allogeneic hematopoietic cell transplantation (HCT); disease control without cure using tyrosine kinase inhibitors (TKIs) or use of interferone. Factors influencing the choice of therapy include: the phase of CML; availability of a donor for HCT; patient age; the presence of medical co-morbidities affecting patient suitability for HCT; and, for patients in earlier phases of CML, the response to treatment with tyrosine kinase inhibitors (TKIs) [*Kantarjian et al., 2007*].